All treated AML patients in both the original and expansion cohorts through January 17, 2025 remain in complete remission. The original cohort of AML patients has reached a median CR of 23.3 months, ...

Patients treated in community settings were more likely to be older, less likely to be White, and had worse survival rates, ...

When blood cancer cells break through the bone and multiply, tumor cells become dangerously diverse and the immune response ...

With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in the most cancer types. | With another trial win, Bristol Myers Squibb is ...